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OBJECTIVE: To describe persistence patterns in the use of statin
therapy in a U.S. managed care population. METHODS: Three
years of pharmacy and eligibility claims data from a managed
care health plan with over two million members were utilized.
Patients with at least one paid statin prescription claim in 2002
were identiﬁed. Those with continuous eligibility for six-month
pre- and two-year post-index statin prescription and no statin
claims in a six-month washout period were included. Patients
with statin prescriptions ﬁlled at mail order pharmacies were
excluded. Individuals were followed for 2 years and proportion
of days covered (PDC) was calculated at 6, 12, 18, and 24
months to assess medication persistence. Days supplied for over-
lapping reﬁlls and last censored ﬁll were adjusted to account for
changes in statin therapy, early reﬁll, and days supplied beyond
the study period. RESULTS: A total of 14,047 patients met the
study criteria. Twenty percent were greater than 65 years of age,
56% were male, 20.5% had at least one diabetes-related pre-
scription, 63.5% had atorvastatin as index drug, and median age
was 55. Mean PDC at 6, 12, 18, and 24 months were 0.63, 0.54,
0.49, and 0.47 respectively. At 6 months, only 42.1% of the
study population remained adherent with their statin therapy,
with PDC of at least 80%. By 24-months, only 26% were adher-
ent. Patients taking diabetes related medications had higher
prevalence of adherence than their non-diabetic counterparts
after 6 months and this trend continued for all subsequent time
intervals over two years (p < 0.002). CONCLUSIONS: Adher-
ence rate of statin therapy remains suboptimal in this managed
care population. Programs to maintain patients on statin therapy
are essential to improve health outcomes and reduce drug
wastage costs due to therapy non-compliance.
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OUTPATIENT DISCONTINUATION AND RESTARTING OF
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OBJECTIVE: To estimate the one-year cumulative incidence of
discontinuation of post-MI beta-blocker therapy after hospital
discharge and the one-year cumulative incidence of restarting
therapy following discontinuation. METHODS: We conducted
a retrospective, population-based, inception cohort study among
all enrollees (n = 1334) of Group Health Cooperative (GHC, a
health maintenance organization) aged 30–79 years who sur-
vived a ﬁrst hospitalized MI during 1986–1996 (mean follow up
1.4 years) and were discharged from the hospital on beta-blocker
therapy. Using the GHC computerized pharmacy database, we
calculated the duration of therapy by assuming subjects were on
average 80% compliant with each beta-blocker prescription ﬁll.
We considered subjects to have discontinued therapy on the 60th
consecutive day they were without medication and to have
restarted therapy on the ﬁrst day they obtained a prescription ﬁll
following discontinuation. In sensitivity analyses, we varied
when we considered subjects to have discontinued therapy (i.e.,
on the 30th and the 90th consecutive day without medication).
We estimated the cumulative incidence using failure time analy-
ses. RESULTS: By one year post-discharge, 511 subjects discon-
tinued therapy; the cumulative incidence of discontinuation was
39.0% (95% CI: 36.3, 41.6). The cumulative incidence increased
to 50.7% (95% CI: 47.9, 53.3) and decreased to 33.4% (95%
CI: 30.9, 36.0) when our discontinuation deﬁnition required 30
and 90 days without medication, respectively. By one year post-
discontinuation, the cumulative incidence of restarting was
42.7% (95% CI: 39.1, 46.2). The cumulative incidence of
restarting increased to 52.9% (95% CI: 49.6, 56.1) and
decreased to 32.0% (95% CI: 28.4, 35.6) when our discontinu-
ation deﬁnition required 30 and 90 days without medication,
respectively. CONCLUSIONS: Our results indicate that patients
are likely to restart post-MI beta-blocker therapy after having
discontinued it. Studies considering only time to ﬁrst discontin-
uation may be oversimplifying the long-term utilization patterns
of therapy by misclassifying patients who subsequently restart.
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MEDICATION ADHERENCE: PREDICTORS AND IMPACT ON
HOSPITALIZATION RISK
Agarwal S, Hansen JE
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OBJECTIVES: The objectives of this study were to investigate
factors associated with adherence to medications for diabetes
and hyperlipidemia, and to assess the impact of adherence on
hospitalization risk. METHODS: Administrative claims and
cash prescriptions data from Wolters Kluwer Health’s IHR data-
base were utilized. This extensive database provides longitudinal
prescription history on about 157 million patients, prescription
and physician services’ history on about 35 million, and pre-
scription, physician services’ and hospitalization history on
about 6 million patients. Adult patients initiating therapy for
either condition between July 2003 and June 2004 and having
claims activity in the 12 months period prior to and following
the index prescription were identiﬁed. A Medication Possession
Ratio °Y´ 80% was considered to be indicative of adherence.
Hospitalization risk was deﬁned as the probability of being
admitted to a hospital in post-index period. Logistic regression
was employed to identify predictors of adherence including: age,
gender, payer type, charlson index, chronic disease score, pres-
ence of disease conditions and pill burden. Relationship between
hospitalization risk and adherence was also modeled using logis-
tic regression after adjusting for the same covariates described
previously. RESULTS: About 48.4% of the 116,607 diabetes
patients and 38.5% of the 285,853 hyperlipidemia patients were
adherent. Predictors of improved adherence in both disease
groups were male gender, being a Medicaid beneﬁciary, a higher
chronic disease score and lower pill burden. Comorbid diseases
including AMI, CAD, CHF, stroke and hyperlipidemia were
associated with higher adherence in the diabetes group. For both
disease conditions, hospitalization risk was signiﬁcantly higher
in non-adherent patients [Diabetes OR: 1.47 (p < 0.0001),
Hyperlipidemia OR: 1.24 (p < 0.0001)]. CONCLUSIONS:
Adherence to therapy is suboptimal for diabetes and hyperlipi-
demia, two chronic diseases that are major drivers of health care
spending. Furthermore, non-adherent patients faced a signiﬁ-
cantly higher risk of hospitalization compared to adherent
patients.
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OBJECTIVES: Examine the relationship of statin noncompli-
ance to subsequent hospitalization among new statin users after
coronary heart disease (CHD) hospitalization. METHODS:
Medstat Marketscan 1999–2002 databases including inpatient,
outpatient and pharmacy claims were utilized for this study. The
ﬁrst statin prescription ﬁll date within six months of CHD hos-
pitalization was identiﬁed as the index date. The sample con-
sisted of adults who had no statin use during the year prior to
the CHD hospitalization and had at least 2-years continuous
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enrollment after the index date. Medication possession ratio
(MPR) was calculated as the ratio of total days supply of statins
to the total days during the ﬁrst year after the index date (initial
use period). Statin noncompliance was deﬁned as having a MPR
less than 80%. The outcome was hospitalization during the year
following the initial use period. Association of statin noncom-
pliance in the initial use period to subsequent hospitalization was
examined by multiple logistic regression, controlling for age,
gender, region, comorbidity, prior hospital admission and
number of drug therapeutic classes in the initial use period.
RESULTS: A total of 3063 subjects met the inclusion criteria and
were included in the analysis. A total of 1170 (38.2%) had a
MPR less than 80% in the initial use period. Compared with
patients who were compliant to statins, noncompliant patients
were about 40% more likely to have a subsequent hospitaliza-
tion (OR: 1.37; 95% CI, 1.13–1.65). Other factors associated
with signiﬁcantly higher risk of subsequent hospitalization
included female gender, older age, higher Charlson comorbidity
index score, higher number of drug therapeutic classes, and prior
hospitalization in the use period. CONCLUSIONS: Statin non-
compliance in the year after CHD hospitalization was common
among new statin users and associated with higher risk of sub-
sequent hospitalization. These ﬁndings suggest that interventions
to improve compliance could reduce risk for hospitalization.
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OBJECTIVE: To identify key drivers of non-persistence on
therapy, using multivariate regression techniques, based on IMS
Disease Analyzer Germany (DA) data. METHODS: DA is a lon-
gitudinal patient database containing de-identiﬁed patient
records collected from 400 practices (290 GPs and 110 Internal
Specialists) treating currently +/-1.3 million patients. We identi-
ﬁed a cohort of hypertensive patients being prescribed valsartan,
metoprolol, ramipril, enalapril, lisonopril, amlodipine or
hydrochlorothiazide (HCTZ), within the period 2003–2004.
Patients had at least 12 months of data prior to, and following
their index date (date of ﬁrst prescription of the study drug
within the window). History of hypertension was deﬁned as the
difference between diagnosis date and index date. Patients who
start on monotherapy of study drugs and those who start on
combination therapy involving at least one of the study drugs
were analyzed separately. Medication persistence was deﬁned as
the total time on a drug, from initiation of therapy to the end of
the last supplied prescription for that drug without intervening
discontinuation. RESULTS: A total of 42,991 patients were
analysed, of whom 61.7% discontinued study medication within
12 months post-index. Cox-regression showed that heart failure
(Hazard Rate to discontinue therapy; HR = 1.04), renal disease
(HR = 1.072), and not being treated with valsartan (HR = 1.07
to 1.359) independently and signiﬁcantly increased the proba-
bility of being non-persistent. Older age (HR = 0.998 per year),
male gender (HR = 0.948), >6mo history of hypertension (HR
= 0.87), dyslipidemia (HR = 0.96), recent stroke (HR = 0.891),
and receiving combination therapy (HR = 0.92) were signiﬁ-
cantly associated with improved persistence. CONCLUSION:
Different demographic and clinical factors are independently
associated with persistence to antihypertensive therapy. Patients
on valsartan were 7 to 36% more likely to persist compared to
patients taking other frequently used antihypertensive medica-
tions. Considering such factors is important to identify patients
most likely to discontinue therapy and to avoid achieving sub-
optimal therapeutic outcomes.
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ADHERENCE MEASURES: SO MANY TO CHOOSE FROM,
WHAT IS THE DIFFERENCE?
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OBJECTIVES: To compare several adherence metrics across dif-
ferent therapeutic conditions, which might complicate these
associations. METHODS: Plan participants dispensed lipid low-
ering, antihypertensive, or selective serotonin reuptake inhibitor
between January 1, and June 30, 2004, had their same class pre-
scriptions extracted for six months before and one year after
their ﬁrst prescription from a large deidentiﬁed US prescription
database. Lipid-lowering (n = 102,067), antihypertensive (n =
139,333), and SSRIs (n = 99,439) plan participants without a
same-class prescription in the pre-period had: number of 
prescriptions—prescription count adjusting 3–1 for mail-retail;
persistent period—ﬁrst minus last ﬁll date; length of exposure—
persistent period plus days supply on last prescription; total
days—sum of all days supply; unique days—sum of days with
exposure to drug; medication possession ratio—sum of days
supply divided by length of exposure (variable) or study period
(ﬁxed); proportion of unique days—sum of days with exposure
divided by length of exposure (variable) or study period (ﬁxed);
and continuous days—days spanned before a break in therapy
calculated over the post-period. Results for these adherence
metrics were divided into equal parts for comparisons.
RESULTS: The measures were grouped into: 1) MPR variable
and PUD variable, 2) unique days 3) MPR ﬁxed, PUD ﬁxed, total
days, length of exposure, and number of prescriptions; 4) per-
sistent period; 5) continuous days. Differences among the groups
started within the ﬁrst 30 days, with group 1 having values less
than 1 percent and the continuous group having more than 20%.
Groups 1 and 2 remained lower than the other groups ending at
about 50% while the others ended at about 70%. CONCLU-
SIONS: Differences in how adherence is calculated needs to be
considered when estimating beneﬁts. Other metrics that account
for dose changes, concomitancy, and other complex regimens
may need further exploration.
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OBJECTIVE: Niacin is highly effective in raising HDL-C, while
lowering LDL-C and triglycerides. However, niacin induced
cutaneous ﬂushing may limit patient acceptance. We compared
the persistency with newly-initiated ER niacin versus other lipid
modifying drug (LMD) classes in recent clinical practice.
METHODS: Administrative claims from the Ingenix Lab/Rx
DatabaseTM were used to identify patients aged >20 years who
were new users (i.e. no prescription from the same LMD class
in the pervious 1-year) of statins, ER niacin, ﬁbrates, bile acid
sequestrants (BAS), or ezetimibe between January 1, 2001 and
June 30, 2003 and were continuously enrolled for 1 year after
LMD initiation. The proportion of days covered (PDC) with
each LMD class was calculated in each quarter (1Q–4Q) and
over the 1-year period after therapy initiation. Patients were
deﬁned as persistent if PDC >= 80%. Generalized linear models
